Sensing Using Neutrophil Activation Probe on the Intensive Therapy Unit

Status Completed

Clinical Trial Summary

Critically ill patients often succumb to acute respiratory disease (rapidly developing disease affecting the lungs). The lungs are the commonest organ to fail and require support in the intensive care environment. However, no accurate methods exist that can be used at the bedside to tell what is causing deterioration in a person's lungs. There are various examples of acute respiratory diseases that can occur as a result of numerous different causes, have a high risk of death and cannot be treated easily with drugs. When trying to accurately diagnose and classify these lung diseases there is a risk that the type of respiratory disease is misdiagnosed, missed or the level of severity is not captured. By using the field of optical molecular imaging and employing novel techniques and technologies, the investigators hope to demonstrate here that a bespoke chemical probe administered in micro doses (tiny doses) directly into the distal lung can rapidly and accurately detect activated neutrophils (cells of the immune system that are implicated in the development of these severe conditions), and so work towards a bedside test which could be used to diagnose, monitor and classify the disease in patients who are critically ill in the future. The population for this study are in intensive care where patients are normally intubated (have a breathing tube) due to the severity of their illness, this may be because of respiratory problems or respiratory problems can rapidly develop. Participants will have the chemical probe administered into their lungs and pictures taken through the tube already in place. As this probe lights up when it comes into contact with neutrophils the investigators will be able to tell if neutrophils are present. This will inform a larger study in which it's hoped that the method can be used to inform clinical decisions. The first procedure will take place within two days of initiation of mechanical ventilation and the direct contact with the study team will be completed within nine days.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02804854
Study type	Interventional
Source	University of Edinburgh
Contact
Status	Completed
Phase	Phase 2
Start date	December 2016
Completion date	July 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02217423` - Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy	N/A
Withdrawn	`NCT02253667` - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients	N/A
Completed	`NCT02345135` - Susceptibility to Infections in Ataxia Telangiectasia	N/A
Completed	`NCT01679301` - Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator	N/A
Terminated	`NCT00966823` - Fetal Tracheal Balloon Study in Diaphragmatic Hernia	Phase 2
Completed	`NCT00139152` - Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair	Phase 4
Completed	`NCT00052052` - An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Phase 2
Completed	`NCT00013949` - Cardiovascular Vulnerability to Particulate Exposure	N/A
Recruiting	`NCT02963467` - Effect of Smoking on Ventilation-Perfusion Ratio	N/A
Recruiting	`NCT02965300` - The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis	N/A
Enrolling by invitation	`NCT02946658` - Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders	Phase 1/Phase 2
Recruiting	`NCT02913365` - Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis	N/A
Completed	`NCT01952002` - Clinical Safety for the Inspiratory Muscle Training	N/A
Completed	`NCT01735526` - Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation	N/A
Recruiting	`NCT01450644` - Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease	Phase 2
Completed	`NCT01215279` - AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)	Phase 2
Completed	`NCT01153321` - Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)	Phase 2
Completed	`NCT00837681` - Pulmonary Complications of Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT02055222` - Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Completed	`NCT01222442` - To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Sensing Using Neutrophil Activation Probe on the Intensive Therapy Unit — SNAP-IT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms